Abstract:Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of all cancer types. A key — yet poorly understood — facet in the disease state is cachexia, a multi-organ pathological state characterized by physical wasting and tissue catabolism. It occurs in 80% of PDAC patients, and to date there are no preventative or early detection methods. Cachexia leads to limited tolerance to anti-cancer therapy and contributes to disease lethality. Here, we present the first-of-its-kind systemic metabolomic analysis across cachectic stages to better understand disease progression. We used the well-established mutant KRASG12D(LSL/+) mutant p53 inducible mouse model of PDAC. Model physiology faithfully recaptures human cachexia: we observe progressive overall weight loss as well as loss of skeletal muscle and adipose tissue. As with human disease, weight loss occurs prior to loss of appetite in the animals, suggesting physiological changes independent of nutrition. Importantly, our model captures the period prior to weight loss (pre-CAC), as well as early-CAC ( 10% weight loss). We profiled the metabolomes of the pancreas, interstitial fluid, plasma, liver, 3 different adipose tissues, and 3 skeletal muscles, from male and female mice, control and tumor-bearing, across all 3 stages of cachexia. Each tissue has a unique metabolic trajectory across cachexia stages; pathway and correlation analyses showed a particular emphasis on lipid alterations in peripheral tissues. Strikingly, we find systemic metabolic changes prior to tissue wasting, including rewiring in the liver before the presence of metastases. This indicates systemic alterations as early as pre-CAC. We therefore used computational modeling to identify metabolites that may be participating in cross-tissue networks. A key finding, confirmed by 13C tracing, was the circulation of lactate and glucose and their uptake by the liver and pancreas. Network maps also suggest lipid rewiring in distal tissues, changes in abundances of these same lipid species in plasma, and their consequent alterations in the tumor and liver. A fundamental question remains: can we predict cachexia development before the manifestation of symptoms? We used feature selection algorithms based on statistical learning, training the models only on a subset of data. Specific sphingolipids and triglycerides were the key lipid species that distinguished control and pre-CAC. We find that the model — trained only on pre-CAC — is able to determine early-CAC with an 85% accuracy and late-CAC with a 90% accuracy. Thus, a limited set of metabolites that are altered in pre-CAC could have predictive value for future cachexia development. Overall, our work provides a resource for the field and advances our understanding of systemic metabolism in PDAC cachexia. We hope this will lay the foundation for cachexia prevention and treatment. Citation Format: Deepti Mathur, Blanca Majem, Courtney Beaulieu, Lucas Dailey, Sarah Jeanfavre, Joao Xavier, Clary Clish, Nada Kalaany. Metabolic patterns of pancreatic cancer cachexia: Cross-tissue lipid networks predict cachexia progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6610.

IRX1 Promotes Loss of Subcutaneous Adipose Tissue by Inhibiting Adipocyte Differentiation in Cachectic Patients with Gastric Cancer

Analysis of Different Adipose Depot Gene Expression in Cachectic Patients with Gastric Cancer

Igfbp-Rp1, A Potential Molecule Associated with Colon Cancer Differentiation

The Effect and Mechanism of Subcutaneous and Visceral Adipose Tissue Loss on Gastric Cancer Patients With Cachexia

Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia

IGFBP-3 promotes cachexia-associated lipid loss by suppressing insulin-like growth factor/insulin signaling

Single-cell sequencing unveils key contributions of immune cell populations in cancer-associated adipose wasting

Abstract 2373: The RNA-binding protein HuR mediates impaired adipogenesis in pancreatic cancer cachexia

The implications of β1 -adrenergic receptor in fat loss in cancer cachexia

Role Of Beta 1-Adrenoceptor In Increased Lipolysis In Cancer Cachexia

Identification and functional analysis of a potential key lncRNA involved in fat loss of cancer cachexia

Alternation of Lipolysis-Pathway Receptors in the Adipocytes of Cancer Cachectic Patients

Low expression of Elovl6 may involve in fat loss in white adipose tissue of cancer-associated cachexia

Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer

Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.

Type 2 immunity is maintained during cancer-associated adipose tissue wasting

The RNA-binding protein HuR impairs adipose tissue anabolism in pancreatic cancer cachexia

Heterogeneous miRNA-mRNA Regulatory Networks of Visceral and Subcutaneous Adipose Tissue in the Relationship Between Obesity and Renal Clear Cell Carcinoma

Identification of ibuprofen targeting CXCR family members to alleviate metabolic disturbance in lipodystrophy based on bioinformatics and in vivo experimental verification

Abstract 6610: Metabolic patterns of pancreatic cancer cachexia: Cross-tissue lipid networks predict cachexia progression

Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia